Sickle Cell Disease Newborn Screening Follow-up Program is sponsored by Department of Health and Human Services (HHS) and Health Resources and Services Administration (HRSA). This program supports newborn screening follow-up for sickle cell disease. While the listed grant is for a specific organization, it indicates ongoing federal interest and funding in this area.

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES ## Maternal and Child Health Bureau ## Division of Services for Children with Special Health Needs ## Sickle Cell Disease Newborn Screening Follow-up Program ## Funding Opportunity Number: HRSA-21-036 ## Funding Opportunity Type(s): New ## Assistance Listings (CFDA) Number: 93. 110 ## NOTICE OF FUNDING OPPORTUNITY # Application Due Date: April 29, 2021 Ensure your SAM. gov and Grants.

gov registrations and passwords are current immediately! HRSA will not approve deadline extensions for lack of registration. Registration in all systems, including SAM.

gov and Grants. gov, may take up to 1 month to complete. Issuance Date: February 22, 2021 Division of Services for Children with Special Health Needs Telephone: (301) 945-9842 Authority: 42 U.S.C.

§ 701(a)(2) (§ 501(a)(2) of the Social Security Act) HRSA-21-036 i The Health Resources and Services Administration (HRSA) is accepting applications for the fiscal year (FY) 2021 Sickle Cell Disease Newborn Screening Follow-up Program.

The purpose of the Follow-Up Program is to facilitate access to quality sickle cell disease (SCD) care by: 1) conducting outreach and working with individuals and families with SCD from the time a newborn screen identifies a child with possible SCD, through diagnosis, treatment and follow-up; 2) providing education to families and providers; 3) disseminating resources; 4) collaborating with state newborn screening programs; and 5) linking individuals and families to community resources, evidence-based SCD care, and care coordination within the communities where they reside to the fullest extent possible.

Funding Opportunity Title: Sickle Cell Disease Newborn Screening Follow-up Program Funding Opportunity Number: HRSA-21-036 Due Date for Applications: April 29, 2021 Anticipated Total Annual Available Estimated Number and Type of Award(s): Up to 20 grants Estimated Award Amount: Up to $184,000 per year subject to the availability of appropriated funds Cost Sharing/Match Required: No Period of Performance: September 1, 2021 through Eligible Applicants: Any domestic public or private entity, including an Indian tribe or tribal organization (as those terms are defined at 25 U.S.C.

§ 450b), is eligible to apply. See 42 CFR § 51a. 3(a).

Domestic faith-based and community-based organizations are eligible to apply. See Section III. 1 of this notice of funding opportunity (NOFO) for complete eligibility information.

HRSA-21-036 ii You (the applicant organization/agency) are responsible for reading and complying with the instructions included in HRSA’s SF-424 Application Guide, available online at http://www. hrsa. gov/grants/apply/applicationguide/sf424guide.

pdf , except where instructed in this NOFO to do otherwise. HRSA has scheduled the following technical assistance: Day and Date: Wednesday, March 17, 2021 Call-In Number: 1- 866-880-0834 Participant Code: 23996302 Weblink: https://hrsa. connectsolutions.

com/hrsa21036/ HRSA will record the webinar and make it available at: https://mchb. hrsa. gov/fundingopportunities/default.

aspx . HRSA-21-036 iii I. PROGRAM FUNDING OPPORTUNITY DESCRIPTION ................................

......................... 1 1. P URPOSE ................................................................................................

............................ 1 2. B ACKGROUND ................................................................................................

..................... 3 II. AWARD INFORMATION ................................................................................................

......... 5 1. T YPE OF APPLICATION AND AWARD ................................................................

..................... 5 2. S UMMARY OF F UNDING ................................................................................................

........ 5 III. ELIGIBILITY INFORMATION ................................................................................................

. 5 1. E LIGIBLE APPLICANTS ................................................................................................

......... 5 2. C OST SHARING /M ATCHING ................................................................................................

.. 5 3. OTHER ................................................................................................................................

6 IV. APPLICATION AND SUBMISSION INFORMATION ................................ ............................

6 1. ADDRESS TO REQUEST APPLICATION P ACKAGE ................................................................ ...

6 2. CONTENT AND F ORM OF APPLICATION SUBMISSION ................................ .............................

6 i. Project Abstract ................................................................................................ ........

9 ii. Project Narrative ................................................................................................ .......

9 iii. Budget ..................................................................................................................... 13 iv.

Budget Narrative .................................................................................................... 13 v. Program-Specific Forms ........................................................................................

14 vi. Attachments ............................................................................................................ 14 3.

D UN AND BRADSTREET DATA U NIVERSAL NUMBERING SYSTEM (DUNS) N UMBER T RANSITION TO THE UNIQUE ENTITY I DENTIFIER (UEI) AND SYSTEM FOR AWARD M ANAGEMENT (SAM) ...... 15 4. S UBMISSION D ATES AND T IMES .........................................................................................

16 5. INTERGOVERNMENTAL REVIEW ........................................................................................... 16 6.

F UNDING RESTRICTIONS .................................................................................................... 16 V. APPLICATION REVIEW INFORMATION .............................................................................

17 1. REVIEW CRITERIA .............................................................................................................. 17 2.

REVIEW AND SELECTION PROCESS .................................................................................... 19 3. A SSESSMENT OF RISK .......................................................................................................

20 VI. AWARD ADMINISTRATION INFORMATION ..................................................................... 21 1.

AWARD NOTICES ............................................................................................................... 21 2. ADMINISTRATIVE AND N ATIONAL POLICY REQUIREMENTS ...................................................

21 3. REPORTING ....................................................................................................................... 22 VII.

AGENCY CONTACTS ........................................................................................................ 23 VIII. OTHER INFORMATION .....................................................................................................

24 HRSA-21-036 1 ## I. Program Funding Opportunity Description This notice announces the opportunity to apply for funding under the Sickle Cell Disease Newborn Screening Follow-up Program (Follow-Up Program).

The purpose of the Follow-Up Program is to facilitate access to quality sickle cell disease (SCD) care by: 1) conducting outreach and working with individuals and families with SCD from the time a newborn screen identifies a child with possible SCD, through diagnosis, treatment and follow-up; 2) providing education to families and providers; 3) disseminating resources; 4) collaborating with state newborn screening programs; and 5) linking individuals and families to community resources, evidence-based SCD care, and care coordination within the communities where they reside to the fullest extent possible.

HRSA funds a portfolio of three coordinated programs to improve outcomes of individuals with SCD and their families: the Follow-up Program (HRSA-21-036), the Sickle Cell Disease Treatment Demonstration Program (TDP) (HRSA-21-032) and the Hemoglobinopathies National Coordinating Center (HNCC) contract.

Together, the programs strengthen the SCD system of care and support by: 1) educating patients, families, and clinicians to improve knowledge and capacities; 2) linking individuals and families to evidence-based care; and 3) fostering partnerships between clinicians, community organizations, and other stakeholders to improve the ability to deliver coordinated, comprehensive care.

The goal of the Follow-up Program is to improve health outcomes for individuals living with SCD by supporting the development of statewide and regional networks of SCD support services and leveraging the expertise of community-based organizations (CBOs) and community health workers (CHWs).

1 The successful applicant will: (1) provide health education and health promotion using evidence-based information for SCD and related issues; (2) develop partnerships with family organizations to ensure that families are empowered as partners in their care; (3) assist families with obtaining SCD educational and social support services; (4) assist with transition services; and (5) engage in activities that help ensure individuals with SCD have access to services, including a medical home, from the time of diagnosis through the lifespan.

Successful recipients will be organizations that demonstrate experience in SCD care, understand the needs of SCD families, knows how to access and link families to community-based services within the region, and is staffed by professionals with knowledge and experience in SCD, including individuals with SCD or their families.

In addition, > 1“A community health worker is a frontline public health worker who is a trusted member of and/or has an unusually close understanding of the community served. This trusting relationship enables the worker to serve as a liaison/link/intermediary between health/social services and the community to facilitate access to services and improve the quality and cultural competence of service delivery.

A community health worker also builds individual and community capacity by increasing health knowledge and self-sufficiency through a range of activities such as outreach, community education, informal counseling, social support and advocacy. ” (Community Health Workers. American Public Health Association.

Retrieved online 6/25/2020: https://www. apha. org/apha-communities/member-sections/community-health-workers ) recipients will work with recipients of the TDP and HNCC to synergize efforts, reduce duplication, and participate in a national Community of Practice.

2 HRSA will fund up to 20 recipients in 20 different states. Up to four awards will be made for activities that support each of the five regions listed below, which have been programmatically designated as HRSA Sickle Cell Disease Regions. 3 It is expected that the four recipients serving each region will work together to support a regional network for SCD support services.

1. Northeast: Connecticut, Massachusetts, Maine, New Hampshire, Rhode Island, Vermont, District of Columbia, Delaware, Maryland, New York, New Jersey, Pennsylvania, Virginia, West Virginia, Puerto Rico, and U.S. Virgin Islands. 2.

Southeast: Alabama, Florida, Georgia, Kentucky, Mississippi, North Carolina, South Carolina, and Tennessee. 3. Midwest: Illinois, Indiana, Michigan, Minnesota, Ohio, Wisconsin, North Dakota, and South Dakota.

4. Heartland and Southwest: Iowa, Missouri, Arkansas, Louisiana, Nebraska, Kansas, Oklahoma, and Texas. 5.

Pacific: New Mexico, Montana, Utah, Wyoming, Colorado, Alaska, Arizona, California, Hawaii, Idaho, Nevada, Oregon, and Washington. • By August 2022, establish a partnership (e.g., Memorandum of Understanding (MOU) or shared work plan) with the TDP recipients within your region and state to develop an action plan to make community-based services accessible to all individuals and families living with SCD within the region.

Examples of activities that might be addressed by the plan include collaborating on: o Linking families to specialty SCD care; o Identifying community-based services in the state and region; o Providing education, support, or disseminating resources through multiple vehicles; or o Linking to the state newborn screening program and/or the state Maternal and Child Health Services Block Grant Program.

• By 2026, 90 percent of individuals and families served by the recipient report receiving care through a primary care medical home and a knowledgeable SCD health care professional. • By 2026, increase by 20 percent from baseline the number of individuals with SCD/families that receive services from the recipient.

Services could include, but are not limited to, the following: o SCD trait counseling and education; o Referrals to medical care; > 2Community of Practice: A group of individuals with shared interest in a specific domain who utilize ongoing communication to broaden their understanding of a topic and identify solutions to common challenges.

In a community of practice, subject matter experts provide resources and information to group participants and group leaders use their expertise to support shared learning by facilitating discussion and collaboration. This strategy results in a dynamic learning environment leading to innovative approaches to solve complex public health issues ( Public Health Information Network Communities of Practice , (2015, March 2).

Centers for Disease Control and Prevention, Atlanta, GA.) > 3These regions align with the Sickle Cell Disease Treatment Demonstration Program (TDP) (HRSA-21-032 ). o Support care coordination; o Referrals to other support services including mental health services, job training, housing etc. • By 2026, reduce by 30 percent the number of individuals and families served by the recipient, who report having unmet needs.

4 The recipient will collect and provide baseline data to HRSA to establish benchmarks for the objectives listed above by the end of year 1 of the award. This program is authorized by 42 U.S.C. § 701(a)(2) (§ 501(a)(2) of the Social Security Act).

Sickle cell disease (SCD) is the most common inherited blood disorder in the United States (U.S.), affecting an estimated 100,000 individuals 5. This lifelong condition disproportionately affects Black (1 of every 365 births) and Hispanic Americans (1 of every 16,300 births) 5 with cases also occurring in individuals of Mediterranean, Middle Eastern, and Asian descent.

SCD causes the body to produce abnormal red blood cells that break forming a sickle shape impeding blood flow and causing anemia, severe pain, organ damage, and other complications including reduced life expectancy.

Early entry into evidence-based care improves health outcomes Over the past 40 years, life expectancy for individuals with SCD has increased significantly due to advances in evidence-based care, including the availability of three U.S. Food and Drug Administration approved medications (i.e., hydroxyurea, crizanlizumab-tmca, and voxelotor).

However, while newborn screening for SCD occurs in every state, many individuals are lost to follow-up or face barriers to accessing high-quality care throughout a lifetime. Many individuals with SCD experience poor health outcomes resulting from persistent barriers to accessing comprehensive, evidence-based care, new medications and therapies, education, care coordination, and other supports.

Many individuals and families live far from SCD specialists and disproportionately access care through the emergency department. During transition from the pediatric to adult health care system, young adults frequently experience an increase in adverse health events including premature death. In addition, discrimination and social determinants of health 6 negatively impact the health of individuals with SCD.

7 > 4Unmet needs include services such as medical, dental, vision, and mental health services as well as other social services provided by community-based organizations. > 5Data and Statistics on Sickle Cell Disease . (2019).

Centers for Disease Control and Prevention, Atlanta, GA. > 6What are social determinants of health? (2020).

Centers for Disease Control and Prevention, Atlanta, GA. > 7Mathur VA et al. Multiple levels of suffering: discrimination in health-care settings is associated with enhanced laboratory pain sensitivity in sickle cell disease.

Clin J Pain; 2016; 32:1076–1085. In September 2020, the National Academies of Sciences, Engineering, and Medicine released a report that included a blueprint and strategies to improve care for individuals with SCD.

The report described the importance of collecting data to measure burden of disease, outcomes and needs of individuals with SCD; the need for organized systems of care to meet both clinical and social needs of individuals with SCD; and the need to increase the number of qualified clinicians providing SCD care 8. HRSA funds three programs that work synergistically to address these issues.

These include the Sickle Cell Disease Treatment Demonstration Program (TDP) (HRSA-21-032) which focuses on educating and increasing the number of health care providers treating individuals with SCD, the Follow-up Program (HRSA-21-036) which focuses on empowering individuals and families to be full partners in their SCD care, and a Hemoglobinopathies National Coordinating Center (HNCC) to facilitate data collection and coordination between the TDP and Follow-up Program.

To extend scarce resources to greatest number of individuals, HRSA provides funding based on a regional approach. Since 2002, through the Follow-Up Program, HRSA has funded activities to support community-based services for individuals with SCD and their families.

Activities included providing technical assistance to SCD CBOs to ensure that individuals and families receive high-quality follow-up including counseling, education, access to a medical home, and referrals to other community-based supports. SCD CBOs are community-based organizations whose primary purpose is serving individuals with sickle cell disease and their families.

In addition, the Follow-up Program previously trained CHWs to work in SCD CBOs. CHWs provide direct services including social support and can improve care and health outcomes for individuals with sickle cell disease. CHWs working in SCD CBOs provide important information on evidence-based guidelines, disease-modifying treatments, and comprehensive services to individuals with SCD and their families who may have limited knowledge of SCD.

9 During the last cycle, SCD CBOs made many partnerships with various organizations. However, there is still a need for additional collaborations at the state and local levels to strengthen the sickle cell disease system of care for individuals with SCD and their families.

In this cycle, the Follow-up Program will focus on: 1) Strengthen SCD CBOs, which are trusted sources of information and support; 2) Strengthen the collaboration between SCD CBOs and other CBOs providing services to individuals with SCD and their family in a state and region; 3) strengthening collaboration with state newborn screening programs and other state public health programs; 4) increasing collaboration with the TDP (HRSA-21-032) to strengthen patient and family engagement and increase educational opportunities for providers; 5) collaborating with the HNCC to develop strategies to reach patients throughout the state to ensure patients have a primary care medical home, access to a knowledgeable specialist; and address families’ unmet needs; 6) utilizing CHWs to conduct outreach and connect individuals and families with education, resources, linkages to knowledgeable SCD providers and other community-based resources; and HRSA-21-036 5 7) engaging Communities of Practice to exchange successful strategies, discuss common challenges, and share lessons learned with other Follow-up Program CBOs.

1. Type of Application and Award Type(s) of applications sought: New. HRSA will provide funding in the form of a grant.

HRSA estimates approximately $3,680,000 to be available annually to fund 20 recipients. You may apply for a ceiling amount of up to $184,000 total cost (includes both direct and indirect, facilities, and administrative costs) per year. The period of performance is September 1, 2021 through August 31, 2026 (5 years).

Funding beyond the first year is subject to the availability of appropriated funds for the Sickle Cell Disease Newborn Screening Follow-up Program (Follow-up Program) in subsequent fiscal years, satisfactory recipient performance, and a decision that continued funding is in the best interest of the Federal Government.

All HRSA awards are subject to the Uniform Administrative Requirements, Cost Principles, and Audit Requirements at 45 CFR part 75 . ## III. Eligibility Information Eligible applicants include any domestic public or private entity, including an Indian tribe or tribal organization (as those terms are defined at 25 U.S.C.

§ 450b), is eligible to apply. See 42 CFR § 51a. 3(a).

Domestic faith-based and community-based organizations are eligible to apply. Cost sharing/matching is not required for this program. > 8Addressing Sickle Cell Disease – A Strategic Plan and Blueprint for Action.

The National Academies of Sciences, Engineering, and Medicine. (2020). https://www.

nationalacademies. org/our-work/addressing-sickle-cell-disease-a-strategic-plan-and-blueprint-for-action#sectionPublications > 9Hsu LL, Green NS, Donnell Ivy E, et al. Community Health Workers as Support for Sickle Cell Care.

Am J Prev Med. 2016;51(1 Suppl 1):S87-S98. HRSA will consider any application that exceeds the ceiling amount non-responsive and will not consider it for funding under this notice.

HRSA will consider any application that fails to satisfy the deadline requirements referenced in Section IV. 4 non-responsive and will not consider it for funding under this notice. NOTE: Multiple applications from an organization are not allowable.

HRSA will only accept your last validated electronic submission, under the correct funding opportunity number, prior to the Grants. gov application due date as the final and only acceptable application. ## IV.

Application and Submission Information 1. Address to Request Application Package HRSA requires you to apply electronically. HRSA encourages you to apply through Grants.

gov using the SF-424 workspace application package associated with this notice of funding opportunity (NOFO) following the directions provided at http://www. grants. gov/applicants/apply-for-grants.

html . 2. Content and Form of Application Submission Section 4 of HRSA’s SF-424 Application Guide provides instructions for the budget, budget narrative, staffing plan and personnel requirements, assurances, certifications, and abstract.

You must submit the information outlined in the Application Guide in addition to the program-specific information below. You are responsible for reading and complying with the instructions included in HRSA’s SF-424 Application Guide except where instructed in the NOFO to do otherwise. You must submit the application in the English language and in the terms of U.S. dollars (45 CFR § 75.

111(a)). See Section 8. 5 of the Application Guide for the Application Completeness Checklist.

The total size of all uploaded files included in the page limit may not exceed the equivalent of 70 pages when printed by HRSA. The page limit includes the abstract, project and budget narratives, attachments, and letters of commitment and support HRSA-21-036 7 required in the Application Guide and this NOFO. Standard OMB-approved forms that are included in the workspace application package do not count in the page limit.

Please note: If you use an OMB-approved form that is not included in the workspace application package for HRSA-21-036, it may count against the page limit. Therefore, we strongly recommend you only use Grants. gov workspace forms associated with this NOFO to avoid exceeding the page limit.

Indirect Cost Rate Agreement and proof of non-profit status (if applicable) do not count in the page limit. It is therefore important to take appropriate measures to ensure your application does not exceed the specified page limit. Any application exceeding the page limit of 70 will not be read, evaluated, or considered for funding.

Applications must be complete, within the maximum specified page limit, and validated by Grants. gov under the correct funding opportunity number prior to the deadline.

Debarment, Suspension, Ineligibility, and Voluntary Exclusion Certification 1) You certify on behalf of the applicant organization, by submission of your proposal, that neither you nor your principals are presently debarred, suspended, proposed for debarment, declared ineligible, or voluntarily excluded from participation in this transaction by any federal department or agency.

2) Failure to make required disclosures can result in any of the remedies described in 45 CFR § 75. 371, including suspension or debarment. (See also 2 CFR parts 180 and 376, and 31 U.S.C.

§ 3321). 3) Where you are unable to attest to the statements in this certification, an explanation shall be included in Attachment 7-15: Other Relevant Documents . See Section 4.

1 viii of HRSA’s SF-424 Application Guide for additional information on all certifications.

Program-Specific Instructions In addition to application requirements and instructions in Section 4 of HRSA’s SF-424 Application Guide (including the budget, budget narrative, staffing plan and personnel requirements, assurances, certifications, and abstract) ensure details related to the following activities are included: Deliver high-quality community-based services and education to individuals living with SCD and their families • Utilize CHWs and other community-based leaders/experts (e.g., peer educators, genetic counselors, social workers, individuals with lived experiences) experienced in providing community-based services to: • Work with state newborn screening programs to identify infants recently screened and diagnosed with SCD and their families and refer them to appropriate primary and specialty care.

• Conduct outreach and partner with primary and specialty care providers and TDP recipients to identify individuals living with SCD and their families who have been lost to follow-up or who do not have a medical home and provide them with services to overcome barriers to receiving primary and specialty care.

Services could include education, counseling, referrals to other community-based resources and linkages to evidence-based SCD, primary and specialty care. HRSA-21-036 8 • Deliver evidence-based interventions that assess transition readiness and develops and implements transition plan to support adolescent transition from pediatric to adult-centered care 10 .

• Utilize existing educational resources and develop new educational resources on an as-needed basis to educate individuals, families, and other lay-stakeholders on topics including SCD, medical home, transition, sickle cell trait, hydroxyurea, evidence-based care guidelines, and other disease modifying therapies.

• Collaborate and coordinate with TDP recipients on patient service referrals, and patient, health professional, and community education. Establish statewide infrastructure of SCD community-based services • Collaborate with recipients of the TDP to develop and implement a plan to make SCD community-based services accessible to all individuals and families living with SCD within the state.

Examples of activities include: o Establishing Memoranda of Understanding/Memoranda of Agreement with other CBO(s) within the state or region. o Establishing a statewide CBO learning collaborative. o Using telehealth to link individuals and families with education and follow-up support.

• Develop both formal and informal partnerships with entities to support community-based services including TDP sites, state newborn screening programs, health departments, Title V agencies, hospitals, health systems, social service organizations, schools, primary care providers and Federally Qualified Health Centers and other SCD CBOs.

Participate in HNCC activities including: • Serve on the National SCD committees and Regional Workgroups to develop and implement strategies that improve access to evidence-based SCD care nationally and within participating states/regions. HNCC Committee/Workgroup activities will address priorities identified in the action plans and other emerging needs at the national, regional and state levels.

• Collaborate with the HNCC to identify individuals with SCD and families to serve on the Steering Committee and Regional Workgroups. • Participate in an annual Follow-up Program/TDP meeting to discuss successes and challenges, identify persistent barriers to evidence-based care and collaborate to develop and implement strategies that increase access to evidence-based SCD care and community-based services.

• Participate in the HNCC-led Community of Practice to identify best and promising practices and innovative strategies on topics including young adult transition, shared decision making and developing statewide networks to identify patients/families that have been lost to follow-up. • Ensure all new CHWs attend the HNCC’s CHW training.

Establish data collection methods and work with the HNCC to evaluate program performance including: assessing the number of infants identified with SCD through newborn screening who have access to a primary care medical home and a > 10 Got Transition. https://www. gottransition.

org/ knowledgeable hematologist within the newborn period, and address families’ unmet needs. • Develop a plan for project sustainability after the period of federal funding ends. See Section 4.

1. ix of HRSA’s SF-424 Application Guide . This section provides a comprehensive framework and description of all aspects of the proposed project.

It should be succinct, self-explanatory, consistent with forms and attachments, and well-organized so that reviewers can understand the proposed project. Successful applications will contain the information below.

Please use the following section headers for the narrative:  INTRODUCTION -- Corresponds to Section V’s Review Criterion(1) Need Briefly describe your organization, the purpose of the proposed project, the methods to be used and projected outcomes.  NEEDS ASSESSMENT -- Corresponds to Section V’s Review Criterion(1) Need Outline the needs of individuals living with SCD in your state.

Provide an estimate of the SCD prevalence in your state. Use and cite demographic data whenever possible to support the information provided. Provide the number of individuals with SCD and families currently being served by your organization and describe the population and unmet health needs you plan to target.

Discuss any relevant barriers in the service area that the project hopes to overcome. This section will help reviewers understand the community you will serve with the proposed project.

 METHODOLOGY -- Corresponds to Section V’s Review Criterion(2) Response Propose methods you will use to address the stated needs and meet each of the previously described program requirements and expectations in this NOFO under Purpose and Program-Specific Instructions .

As appropriate, include development of effective tools and strategies for ongoing staff training, outreach, collaborations, clear communication, and information sharing/dissemination with efforts to involve individuals with SCD, families, and communities. Specifically describe how you will engage with individuals living with SCD and families in all aspects of the project including planning, implementation and monitoring.

Include a description of any innovative methods you will use to address the stated needs. Describe a plan for creating a statewide infrastructure of SCD CBO services, and how you will collaborate with state newborn screening programs and TDP recipients to ensure CBO services are accessible to all individuals and families living with SCD within your state.

HRSA-21-036 10 Describe how you will utilize CHWs and other community-based leaders/experts (e.g., peer educators, genetic counselors, social workers, individuals with lived experience) to deliver high-quality services and education to individuals living with SCD and their families. Describe how many individuals with SCD or their families will be served through the project activities.

Propose a plan for project sustainability after the period of federal funding ends. HRSA expects recipients to sustain key elements of their projects, e.g., strategies or services and interventions, which have been effective in improving practices and those that have led to improved outcomes for the target population.

Include a plan to disseminate reports, products, and/or project outputs so key target audiences receive the project information.  WORK PLAN -- Corresponds to Section V’s Review Criteria(2) Response and (4) Both a work plan and logic model are required. Although there are similarities, a logic model is not a work plan.

A work plan is an “action” guide with a time line used during program implementation; the work plan provides the “how to” steps. You can find additional information on developing logic models at the following website: https://www. acf.

hhs. gov/archive/ana/training-technical-assistance/ana/resource/ana/resource/logic-model-template . Submit a work plan (Attachment 1) to describe the activities or steps you will use to achieve each of the objectives proposed during the entire period of performance in the Methodology section.

Use a time line that includes each activity and identifies responsible staff. As appropriate, identify meaningful support and collaboration with key stakeholders in planning, designing, and implementing all activities, including developing the application. Submit a logic model (Attachment 1) for designing and managing the project.

A logic model is a one-page diagram that presents the conceptual framework for a proposed project and explains the links among program elements.

While there are many versions of logic models, for the purposes of this notice, the logic model should summarize the connections between the: Goals of the project (e.g., reasons for proposing the intervention, if applicable); Assumptions (e.g., beliefs about how the program will work and support resources).

Base assumptions on research, best practices, and experience; Inputs (e.g., organizational profile, collaborative partners, key personnel, budget, other resources); Target population (e.g., the individuals to be served); Activities (e.g., approach, listing key intervention, if applicable); HRSA-21-036 11 Outputs (i.e., the direct products of program activities); and Outcomes (i.e., the results of a program, typically describing a change in people or systems).

 RESOLUTION OF CHALLENGES -- Corresponds to Section V’s Review Criterion (2) Response Discuss challenges that you are likely to encounter in designing and implementing the activities described in the work plan, and approaches you will use to resolve such challenges. Specifically address how you will overcome barriers to identifying individuals who have been lost to follow-up and ensure access to SCD services throughout the state.

 EVALUATION AND TECHNICAL SUPPORT CAPACITY -- Corresponds to Section V’s Review Criteria (3) Evaluative Measures and (5) Describe the plan for the program performance evaluation that will include measuring and evaluating progress on the program objectives, including proposed measures and data collection procedures.

In addition, include descriptions of the inputs (e.g., organizational profile, collaborative partners, key personnel, budget, and other resources), key processes, and expected outcomes of the funded activities.

Describe the systems and processes that will support your organization's performance management requirements through effective tracking of performance outcomes, including a description of how the organization will collect and manage data (e.g., assign skilled staff, data management software) in a way that allows for accurate and timely reporting of performance outcomes.

As appropriate, describe the data collection strategy to collect, analyze and track data to measure process and impact/outcomes, and explain how the data will be used to inform program development and service delivery. Describe any potential obstacles for implementing the program performance evaluation and your plan to address those obstacles.

Within the proposed evaluation plan, describe how the following information will be tracked and reported in the annual progress report during the period of performance: o Number of individuals with SCD/families served and the types of services provided.

Services could include:  SCD trait counseling and education;  Referrals to medical care;  Support care coordination;  Referrals to other support services including mental health services, job training, housing etc. o Number of individuals with SCD/families referred to a knowledgeable SCD health care